Last reviewed · How we verify
NCT03644771: Acthar
Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function
trial testing Acthar in Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function in 40 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Greater Boston Medical Associates |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 25 January 2017 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Acthar — full drug profile →
Conditions studied
- Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function — all drugs for Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function →
Sponsor
Greater Boston Medical Associates
Who can join
Adults 18 to 75, any sex, with Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with proteinuria to start treatment with Acthar and watch a variety of clinical parameters with a goal of decreasing proteinuria between 50-100% over a period of nine months with every 3 months increasing the dose of medication until a decrease of either 50- 100 % of protein excretion is achieved. In addition addition podocyte function will be assessed monthly by measuring suPar levels, tnf alpha, podocyte/creatinine levels as well as podocyte function studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03644771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acthar
Trials testing the same drug.
- NCT04169061 — Impact of Acthar on Everyday Life of Participants With Severe Keratitis · Phase 4 · completed
- NCT02683889 — Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation · Phase 3 · completed
- NCT02541955 — Use of Acthar in Rheumatoid Arthritis (RA) Related Flares · Phase 4 · completed
- NCT03068754 — Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) · Phase 2, PHASE3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03644771 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Greater Boston Medical Associates
- Last refreshed: 5 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03644771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing